Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation

Submitted: April 27, 2018
Accepted: May 11, 2018
Published: June 7, 2018
Abstract Views: 2943
PDF: 516
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Old age remains one of the strongest risk factors for stroke in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is the most effective way to prevent thromboembolic disease in patients with atrial fibrillation (AF). Until few years ago, aspirin and vitamin-K antagonists (VKAs) were the primary agents used to prevent thromboembolic disease in patients with AF. The approval of non–vitamin K oral anticoagulants (NOACs) has now expanded the range of therapeutic agents available to providers. The authors highlight practical considerations regarding the selection and use of OAC in older adults to aid clinical decision making.



PlumX Metrics


Download data is not yet available.


How to Cite

Palleschi, Lorenzo, and Eleonora Nunziata. 2018. “Net Clinical Benefit of Anticoagulation Therapy in the Elderly Patients With Atrial Fibrillation”. Monaldi Archives for Chest Disease 88 (2).